Moreover, FT@XBP1 alleviated hepatic steatosis, injury, and fibrosis in an FFC diet-induced MASH model, while the impact of FT@XBP1 on HSCs in vitro was almost negligible. The gene discussed is XBP1; the disease is metabolic dysfunction-associated steatohepatitis.